Business Wire

1E

1.10.2020 13:16:05 CEST | Business Wire | Press release

Share
IT Departments that aren’t Listening to Employees Will Fail in 2021, says 1E

Endpoint automation leader 1E has announced new features to their market leading digital experience management offering, Tachyon Experience, helping enterprises truly understand how users experience their IT.

Sentiment as a leading indicator in a Remote First World

In a remote first world, knowledge workers increasingly rely on their endpoint to be performant and responsive; The endpoint is their entire conduit to the workplace. Recent research by Vanson Bourne showed that the overwhelming majority (98%) of remote workers found endpoint performance to be important, yet more than half (53%) saying that their machine runs more slowly outside the office. IT has historically lacked the tools to identify and remediate these issues. Tachyon Experience has been built to provide IT analytics of the aggregated digital experience of users across the entire endpoint estate down to the sentiment of an individual user.

“Almost every knowledge worker is working remotely, but they have an inferior experience to working in the office. Businesses that succeed in a remote first world will provide a first class digital experience to all employees wherever they are. IT departments need tools which monitor digital experience, gather employee sentiment and remediate issues as they happen.” said Sumir Karayi, CEO and Founder, 1E

Tachyon Sentiment joining up previously siloed datasets

Integration is where Tachyon Sentiment differentiates over the traditional survey approach; Traditionally, IT departments have conducted periodic NPS polls, but this has rarely been joined up to the applications and device they’re using. This siloed approach to data clouds any real digital experience insights. For the first time, IT departments are able to correlate a user’s sentiment or perception of IT with actual telemetry from the endpoint that they’re using. Tachyon Experience aggregates end user sentiment with endpoint metrics (stability, performance and responsiveness) into a single, overarching Digital Experience score.

“Sentiment is a vital expansion to our Tachyon Experience offering as it allows IT departments the ability to identify users that appear to be having a solid experience from a technical metrics perspective, but in reality, are having a frustrating time with some of their applications or day to day end point experience”, says Rob Peterscheck, VP of Product for 1E

The new Sentiment capability in 1E Tachyon Experience introduces unparalleled flexibility and integration in comparison to traditional approaches to gathering user feedback. Users can be polled on an ad-hoc basis, scheduled or in response to a specific event (for example an IT change or upgrade). “The ability to collect user feedback in real time in response to major transformation initiatives or rollouts will also be a major asset to IT operations teams who have previously used trailing indicators such as escalation of service desk tickets” said Peterscheck.

Digital Experience, not just the purview of the IT department

The addition of Sentiment to Tachyon Experience marks a vital step in a market shift to broaden the appeal of Digital Experience Monitoring tools beyond the IT department. “Given the challenges of remote working for employees and the tighter relationship between HR and IT, we see the Tachyon Experience playing a part in further desiloing data and toolsets between our departments. HR routinely ask employees how they feel about their workplace using traditional tools, but in this new world, the laptop is their workplace and hence it makes sense to share the data between the departments” said Nick Bartlett, Chief People Officer for 1E

For more information on 1E Tachyon Experience, attend the launch webinar on 15th of October at https://info.1e.com/tachyon-sentiment-launch or visit www.1E.com .

Statistics referenced throughout are taken from 1E’s latest research ‘The new digital workplace: employee experiences with universal remote working since COVID’. You can read the full research here: www.1E.com/wfa-research

####

About 1E

1E offers the only real-time remote endpoint automation solution that helps IT actively manage employee experience in real-time. Giving IT teams total control and visibility over all remote endpoints, Tachyon offers in-depth analytics to understand and improve the experience employees have with their endpoints. It delivers

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye